Correlation of serum C-reactive protein and procalcitonin levels in infections of kidney transplant recipients

Year 2017, Volume: 3 Issue: 2, 135 - 139, 04.07.2017

Nurettin Ay , Melih Anil Vahhac Alp Safak Kaya , Neslihan Cicek Ozgur Arslan

https://doi.org/10.18621/eurj.291746

Abstract

Objectives. Procalcitonin is a propeptide of
calcitonin and has been increasingly used as a biomarker of infection. The aim
of this study was to evaluate correlation of serum C-reactive protein (CRP) and
procalcitonin (PCT) levels of kidney transplant patients hospitalized due to
infection. Methods. There were 121 patients who had kidney transplant in
our center between September 2012 and February 2017 and patients with a
diagnosis of infection or rejection were included in the study. Simultaneous
106 serum CRP and PCT levels at the beginning or during any time of treatment
for post-transplant infection, cytomegalovirus (CMV) positivity, BK viremia and
rejection were evaluated. Results. Median and
interquartile ranges of CRP and PCT serum levels were 40 mg/l [24.7-64.9] and 0.19
ng/ml [0.1-0.61], respectively. A significant positive correlation between
serum CRP and PCT levels of the patients were observed (r=0.490, p<0.001). When serum CRP levels were
grouped as <50 mg/l, 50-100 mg/l and >100 mg/l, correlations with serum
PCT levels were as r=0.461 (p<0.001),
r=-0.52 (p=0.860) and r=0.488 (p=0.153), respectively. Serum levels of PCT did not increase in CMV and BK virus
infections and rejection. Conclusions. Serum CRP and PCT levels
were correlated as a whole in the study, whereas serum CRP levels of 50-100 mg/l
and >100 mg/l did not show a statistically significant correlation.
Stability of PCT levels in viral infections and rejections might be an
advantage for the follow-up of solid organ transplants. We need prospective
trials of PCT measurements for the evaluation of post-transplant infections. 

Keywords

C-reactive protein, procalcitonin, correlation, kidney transplantation

References

• [1] Savas Bozbas S, Er Dedekarginoglu B, Ulubay G, Haberal M. Role of serum procalcitonin levels in solid-organ transplant patients. Exp Clin Transplant 2016;14(Suppl 3):116-20.
• [2] Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, El-Amm JM, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. ClinTransplant 2006;20:401-9.
• [3] Ariza-Heredia EJ, Beam EN, Lesnick TG, Cosio FG, Kremers WK, Razonable RR. Impact of urinary tract infection on allograft function after kidney transplantation. Clin Transplant 2014;28:683-90.
• [4] Lee JR, Bang H, Dadhania D, Hartono C, Aull MJ, Satlin M, et al. Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: a single-center report of 1166 kidney allograft recipients. Transplantation 2013;96:732-8.
• [5] Pelle G, Vimont S, Levy PP, Hertig A, Ouali N, Chassin C, et al. Acute pyelonephritis represents a risk factor impairing long-term kidney graft function. Am J Transplant 2007;7:899-907.
• [6] Hammer S, Meisner F, Dirschedl P, Hobel G, Fraunberger P, Meiser B, at al. Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Transpl Immunol 1998;6:235-41.
• [7] Le Moullec JM, Jullienne A, Chenais J, Lasmoles F, Guliana JM, Milhaud G, et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984;167:93-7.
• [8] Whicher J, Bienvenu J, Monneret G. Procalcitonin as an acute phase marker. Ann Clin Biochem 2001: 38(Pt 5):483-93.
• [9] Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010:48:2325-9.
• [10] Sandkovsky U, Kalil AC, Florescu DF. The use and value of procalcitonin in solid organ transplantation. Clin Transplant 2015;29:689-96.
• [11] Dumea R, Siriopol D, Hogas S, Mititiuc I, Covic A. Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. Int Urol Nephrol 2014;46:461-8.
• [12] Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20.
• [13] Dikici N, Ural O, Ertap F, Sumer S, Kara F. Training to prevent healthcare associated infections. Eur Res J 2015;1:94-105.
• [14] Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, et al. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol 2013;47:12-20.
• [15] Cooper D, Sharples L, Cornelissen J, Wallwork J, Alexander G, Trull A. Comparison between procalcitonin, serum amyloid A, and C-reactive protein as markers of serious bacterial and fungal infections after solid organ transplantation. Transplant Proc 2001;33:1808-10.
• [16] Roques M, Chretien ML, Favennec C, Lafon I, Ferrant E, Legouge C, et al. Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis. Mycoses 2016;59:383-90.
• [17] Hammer C, Fraunberger P, Meiser B, Hammer S. Procalcitonin:a new marker for diagnosis of acute rejection and nonviral infection of heart and lung transplant patients. Transplant Proc 2001:33:2204-6.
• [18] Eberhard OK, Langefeld I, Kuse ER, Brunkhorst FM, Kliem V, Schlitt HJ, et al. Procalcitonin in the early phase after renal transplantation--will it add to diagnostic accuracy? ClinTransplant 1998;12:206-11.